V
Velarion™Intelligence
Sign InFree TrialBook a Walkthrough

RAPT Therapeutics Executive Compensation (FY24)

RAPT · Executive and director compensation, fiscal 2023 to 2024

The paid brief on RAPT Therapeutics

Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.
$1,500 for the Executive Compensation Report. Both reports for $2,400.
Data as of September 7, 2026Latest filing (8-K): May 29, 2025
3 filings cited on this page
A report that fails to generate is refunded in full
Published by Velarion Company Intelligence
RAPT Therapeutics brief$1,500Get the executive brief
96 figures on this page: 95 cited to the filing that reported them, 1 calculated from figures it prints. See the citations
Chief executive, fiscal 2024
◇
Brian Wong
Latest say-on-pay support
=
May 29, 2025

More on RAPT Therapeutics

Five data products on this company. Each one is requested through the developer setup page.
What changed from fiscal 2023 to fiscal 2024
The figures that moved, and by how much. Analysis of these figures is part of the Velarion platform.
Chief executive total compensation — Brian Wong: $6,591,617 → $6,979,539 (5.9% higher)

Frequently asked questions

Answers drawn from the data on this page.
Who is RAPT Therapeutics' chief executive and what were they paid?
Brian Wong, President and Chief Executive Officer, received $6,979,539 in total compensation for fiscal 2024. Wong's total moved 5.9% higher from the $6,591,617 reported for fiscal 2023.
What was RAPT Therapeutics' say-on-pay result?
Shareholders supported the say-on-pay proposal with 76.5% of votes cast for or against in favor at the meeting held May 29, 2025 for fiscal 2024.

Executive compensation

Every element reported for each named executive officer, by fiscal year.
Fiscal 2023
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Brian Wong
President and Chief Executive Officer
◇——◇◇—◇◇
Rodney Young
Chief Financial Officer
◇——◇◇—◇◇
William Ho
Chief Medical Officer
◇——◇◇—◇◇
Fiscal 2024
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Brian Wong
President and Chief Executive Officer
◇——◇◇—◇◇
Rodney Young
Chief Financial Officer
◇——◇◇—◇◇
William Ho
Chief Medical Officer
◇——◇◇—◇◇
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. A negative change in pension value is shown but, as the company reports it, not included in the total.

Outstanding awards

Awards still held at fiscal year end.
As disclosed at fiscal 2024 year end
OfficerAwardUnvested unitsMarket value of unvested unitsExercise priceExpires
Brian WongRSU◇◇——
RSU◇◇——
RSU◇◇——
RSU◇◇——
RSU◇◇——
RSU◇◇——
William HoRSU◇◇——
RSU◇◇——
RSU◇◇——
RSU◇◇——
RSU◇◇——
RSU◇◇——
Rodney YoungRSU◇◇——
RSU◇◇——
RSU◇◇——
RSU◇◇——
RSU◇◇——
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.

Director compensation

What each non-employee director was paid.
Fiscal 2024
DirectorFees earned in cashStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
William Rieflin
◇—◇———◇
Mary Ann Gray
◇—◇———◇
Michael Giordano
◇—◇———◇
Wendye Robbins
◇—◇———◇
Lori Lyons-Williams
Board chair
◇—◇———◇
Linda Kozick
◇—◇———◇
Brian Wong served on the board in fiscal 2024 and received no compensation for board service. Executive directors are typically paid through their executive roles, shown above.
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.

Director fee schedule

The standing retainers and premiums the board pays, as published.
Board cash retainer◇
Board equity retainer◇
Total board retainer◇
Board chair premium◇
Audit committee chair◇
Audit committee member◇
Compensation committee chair◇
Compensation committee member◇
Nominating and governance chair◇
Nominating and governance member◇
Equity is delivered as Options.

Disclosed peer group

The companies this board named as its compensation comparison group. The list is disclosure; the comparison is analysis.

Say-on-pay history

Shareholder support for the compensation program, by year.
YearMeetingSupportVotes forVotes againstAbstentions
2024May 29, 2025=◇◇◇
Email me this page as a cited PDF
The same figures, the same citations, formatted to hand to a committee. Nothing is added that is not on this page.
Your address is used for this and nothing else. Unsubscribe in one click.
Tell me when RAPT Therapeutics files
You get a note when this company’s compensation data changes.
Your address is used for this and nothing else. Unsubscribe in one click.

What this page does not include

Everything above is a fact RAPT Therapeutics disclosed, and it is free. Everything below is our analysis of those facts, and it is not.
Written compensation analysis
A read of the pay program as designed and as paid: incentive structure, goal rigor, the alignment between the committee's stated philosophy and what the numbers show.
Executive Compensation Report — $1,500
Board and governance analysis
Committee composition, independence, director pay positioning, and the governance provisions read together rather than listed.
Board Governance Report — $1,200
Realizable pay
What the awards above are actually worth today against what they were valued at on grant, and what the gap says about the pay-for-performance link.
Velarion Intelligence
Adviser switching and vote outcomes
Two datasets covering compensation-adviser changes and what followed a contested vote. Both are part of the Velarion platform.
Inquire about access
Multiple companies at once
Cross-company views, cohort screens, and data export across the industries we cover. This page is one company; the platform is all of them.
Velarion Intelligence
Join the list for a Velarion Pro seat
Full platform access for one person: every industry we cover, peer positioning, and the written analysis. We will email you when it opens.
Your address is used for this and nothing else. Unsubscribe in one click.
Join the list for Peer Group Review
Whether RAPT Therapeutics' disclosed peer group is defensible, who names RAPT Therapeutics back in their own benchmarking group, and how pay tracks performance across it. This is the analysis a compensation consultant delivers on the group above. We will email you when it opens.
Your address is used for this and nothing else. Unsubscribe in one click.

Citations

Every figure on this page is cited to the document that reported it. Select any figure to see its citation.
96 figures on this page: 95 cited to the filing that reported them, 1 calculated from figures it prints.
95 cited to the filing
1 calculated from the filing

Documents cited

  1. 0000950170-25-079023
  2. 0000950170-25-053517
    DIRECTOR COMPENSATION · Director Compensation for the year ended December 31, 2024 · Outstanding Equity Awards at December 31, 2024 · Summary Compensation Table
  3. 0001193125-24-088453
    Summary Compensation Table
Cite this data
This page is free to cite. Attribution we ask for:
Velarion, “RAPT Therapeutics executive compensation, FY2023–FY2024.” https://intel.velarion.ai/comp/RAPT (accessed 2026).
Short form: data: Velarion

The paid brief for RAPT Therapeutics

Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.
$1,500 for the Executive Compensation Report. Both reports for $2,400.
Get the executive briefGet the board briefNo account needed.
3 filings cited on this page
Method: intel.velarion.ai/methodology
A report that fails to generate is refunded in full
Published by Velarion Company Intelligence
Embed this data
A small, cited view of this data for your own page or newsletter. Every embed carries a visible link back here, so the attribution travels with it.
The headline figures, each with its citation.
Connect an AI assistant
Ask your own assistant about RAPT Therapeutics and roughly 3,000 other US public companies, and get back the same figures on this page with the same citations. Free read access, no account. Add this to your assistant's connector settings.
Setup guide and the full list of questions it answers

Free to read and cite. Redistribution or bulk use of the dataset requires a data license. Talk to us about the data license.

Cite this data
APA
Velarion Company Intelligence. (2026). Velarion database: executive and board compensation data (Version 2026Q3) [Data set]. Zenodo. https://doi.org/10.5281/zenodo.22283854
BibTeX
@misc{velarionData2026,
  author = {{Velarion Company Intelligence}},
  title = {Velarion database: executive and board compensation data},
  year = {2026},
  version = {2026Q3},
  doi = {10.5281/zenodo.22283854},
  publisher = {Zenodo},
  url = {https://doi.org/10.5281/zenodo.22283854}
}
For informational purposes only. Not investment, legal, or compensation advice.  All companies · The Pay Desk · Methodology · Terms · Privacy